Montesino et al., 2012 - Google Patents
Structural characterization of N-linked oligosaccharides on monoclonal antibody Nimotuzumab through process developmentMontesino et al., 2012
View PDF- Document ID
- 3400504538025444585
- Author
- Montesino R
- Calvo L
- Vallin A
- Rudd P
- Harvey D
- Cremata J
- Publication year
- Publication venue
- Biologicals
External Links
Snippet
Nimotuzumab (TheraCIM, CIMAher, h-R3, humanized anti-EGF-R antibody), monoclonal antibody (mAb) manufactured at the Center of Molecular Immunology (Havana, Cuba) is currently being tested in several clinical trials. Nimotuzumab has a single N-glycosylation …
- 150000002482 oligosaccharides 0 title abstract description 35
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beck et al. | Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins | |
| Del Val et al. | Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns | |
| Flynn et al. | Naturally occurring glycan forms of human immunoglobulins G1 and G2 | |
| Wang et al. | Antibody glycosylation: impact on antibody drug characteristics and quality control | |
| Müthing et al. | Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti‐melanoma mouse IgG3 monoclonal antibody R24 | |
| Mimura et al. | Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry | |
| US10352943B2 (en) | A-fucosylation detection in antibodies | |
| CA2922888C (en) | Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof | |
| Montesino et al. | Structural characterization of N-linked oligosaccharides on monoclonal antibody Nimotuzumab through process development | |
| EP2768845B1 (en) | Separation method for fucosylated antibodies | |
| US20240384238A1 (en) | Antibodies with modulated glycan profiles | |
| EP2791164B1 (en) | Non-fucosylated glycoprotein comprising the Fc domain of an antibody | |
| Hammura et al. | Synthetic glycopeptides allow for the quantitation of scarce nonfucosylated IgG Fc N-glycans of therapeutic antibody | |
| EP2141237A1 (en) | Method for reducing the fucose content of recombinant proteins | |
| US20220177582A1 (en) | Non-consensus glycosylation of bispecific antibodies | |
| US20150210777A1 (en) | Glycoprotein | |
| Harris et al. | Analytical characterization of monoclonal antibodies: linking structure to function | |
| Jäger et al. | Determination of antibody glycosylation by mass spectrometry | |
| Janin-Bussat et al. | Antibody glycans characterization | |
| ABRAHAMS et al. | YUSUKE MIMURA, ROY JEFFERIS, YUKA MIMURA-KIMURA | |
| Higel et al. | N-glycosylation heterogeneity and the influence on structure, function | |
| Meuris et al. | GlycoDelete technology: simplifying mammalian cell N-glycosylation for recombinant protein expression | |
| ZHENG et al. | 1 CHARACTERIZATION OF MONOCLONAL ANTIBODY HETEROGENEITY BY HPLC ANALYSIS |